[go: up one dir, main page]

NO971537L - Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser - Google Patents

Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser

Info

Publication number
NO971537L
NO971537L NO971537A NO971537A NO971537L NO 971537 L NO971537 L NO 971537L NO 971537 A NO971537 A NO 971537A NO 971537 A NO971537 A NO 971537A NO 971537 L NO971537 L NO 971537L
Authority
NO
Norway
Prior art keywords
inhibitors
metalloproteases
therapeutic use
peptidyl compounds
compounds
Prior art date
Application number
NO971537A
Other languages
English (en)
Other versions
NO971537D0 (no
Inventor
John Montana
Andrew Douglas Baxter
David Alan Owen
Robert John Watson
Neil Phillipson
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420057A external-priority patent/GB9420057D0/en
Priority claimed from GBGB9504907.8A external-priority patent/GB9504907D0/en
Priority claimed from GBGB9509431.4A external-priority patent/GB9509431D0/en
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of NO971537D0 publication Critical patent/NO971537D0/no
Publication of NO971537L publication Critical patent/NO971537L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO971537A 1994-10-05 1997-04-04 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser NO971537L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420057A GB9420057D0 (en) 1994-10-05 1994-10-05 Compounds
GBGB9504907.8A GB9504907D0 (en) 1995-03-10 1995-03-10 Compounds
GBGB9509431.4A GB9509431D0 (en) 1995-05-10 1995-05-10 Compounds
PCT/GB1995/002362 WO1996011209A1 (en) 1994-10-05 1995-10-05 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases

Publications (2)

Publication Number Publication Date
NO971537D0 NO971537D0 (no) 1997-04-04
NO971537L true NO971537L (no) 1997-06-04

Family

ID=27267412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971537A NO971537L (no) 1994-10-05 1997-04-04 Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser

Country Status (19)

Country Link
US (2) US5994312A (no)
EP (1) EP0784629B1 (no)
JP (1) JP3787605B2 (no)
CN (1) CN1193978A (no)
AT (1) ATE179431T1 (no)
AU (1) AU695796B2 (no)
BR (1) BR9509237A (no)
CA (1) CA2201639A1 (no)
CZ (1) CZ288436B6 (no)
DE (1) DE69509401T2 (no)
DK (1) DK0784629T3 (no)
ES (1) ES2133807T3 (no)
FI (1) FI971412L (no)
GR (1) GR3030751T3 (no)
HU (1) HUT77282A (no)
MX (1) MX9702487A (no)
NO (1) NO971537L (no)
PL (1) PL183510B1 (no)
WO (1) WO1996011209A1 (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692102B2 (en) * 1995-05-10 1998-05-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
DE69624477T2 (de) * 1995-05-10 2003-06-26 Darwin Discovery Ltd., Cambridge Peptide, die metallproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
US5981491A (en) * 1995-05-10 1999-11-09 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
JPH11504934A (ja) * 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
CN1145637C (zh) * 1995-10-05 2004-04-14 达尔文发现有限公司 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
CZ291337B6 (cs) * 1995-11-22 2003-02-12 Darwin Discovery Limited Merkaptoalkylpeptidylová sloučenina, její použití pro výrobu přípravku pro léčení nebo prevenci stavu souvisejícího s metalloproteinázou nebo TNFalfa a farmaceutický přípravek ji obsahující
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
KR100338861B1 (ko) 1996-01-23 2003-02-20 시오노기세이야쿠가부시키가이샤 술폰화아미노산유도체및이를함유한메탈로프로테이나제저해제
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6013649A (en) * 1996-07-22 2000-01-11 Monsanto Company Thiol sulfone metalloprotease inhibitors
JP2000515153A (ja) * 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6429212B1 (en) 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
BR9712081B1 (pt) * 1996-08-28 2010-12-14 derivado peptÍdico, composto, composiÇço farmacÊutica e composiÇço para ativar o sistema nervoso central.
CN1150205C (zh) * 1996-09-19 2004-05-19 阿温蒂斯药物公司 用作基质金属蛋白酶抑制剂的3-巯基乙酰氨基-1.5-二取代的-2-氧代-氮杂环庚烷衍生物
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
PT946166E (pt) * 1996-12-17 2004-06-30 Warner Lambert Co Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
AU741903C (en) * 1997-03-03 2002-09-05 Darwin Discovery Limited Selective MMP inhibitors having reduced side-effects
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
AU750130B2 (en) 1997-03-04 2002-07-11 Monsanto Company Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US6319902B1 (en) 1997-08-22 2001-11-20 Shionogi & Co., Ltd. Peptide derivatives having thiazolyl-alanine residue
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
AU756150C (en) 1997-11-14 2004-03-04 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
CA2347911A1 (en) 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
EP1150976B1 (en) * 1998-12-31 2003-02-26 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6486193B2 (en) * 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
GEP20043238B (en) 1999-02-08 2004-05-25 Searle & Co Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
CA2409035A1 (en) 2000-05-15 2001-11-22 Darwin Discovery Limited Hydroxamic acid derivatives
PT1365787E (pt) * 2000-08-25 2007-06-29 Res Corp Technologies Inc Utilização de anticonvulsivantes de aminoácidos para tratamento da dor.
US7129256B2 (en) 2000-08-31 2006-10-31 Shionogi & Co., Ltd. Antiparkinsonism drugs
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
EP1243263B1 (en) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
BR0209525A (pt) 2001-05-11 2004-03-09 Pharmacia Corp Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease
EA021242B9 (ru) 2001-06-26 2015-11-30 Эмджен Фримонт Инк. Антитела к остеопротегерин лиганду (опгл)
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
EP1501827A2 (en) 2002-04-25 2005-02-02 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors
MXPA05000171A (es) * 2002-06-25 2005-04-08 Pharmacia Corp Acido arilsulfonilhidroxamico y derivados de amida y su uso como inhibidores de la proteasa.
EP1585555A2 (en) * 2002-12-27 2005-10-19 Angiotech International Ag Compositions and methods of using collagen and mmpi
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20040259744A1 (en) * 2003-12-19 2004-12-23 Meidong Yang Skin and hair cleansers containing sulfur
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
NZ552651A (en) 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
WO2008029168A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2009048541A2 (en) * 2007-10-05 2009-04-16 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
WO2013016531A2 (en) * 2011-07-26 2013-01-31 Purdue Research Foundation Compounds and methods for use in treating neoplasia and cancer
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN110143892B (zh) * 2019-06-21 2022-08-12 江苏豪森药业集团有限公司 莫沙必利中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113715A (en) * 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
US4235885A (en) * 1979-06-25 1980-11-25 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
US4263293A (en) * 1980-05-30 1981-04-21 E. R. Squibb & Sons, Inc. Heterocyclic containing amides as inhibitors of mammalian collagenase
US4382081A (en) * 1981-06-12 1983-05-03 E. R. Squibb & Sons, Inc. Inhibitors of mammalian collagenase
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
AU687436B2 (en) * 1993-08-23 1998-02-26 Immunex Corporation Inhibitors of TNF-alpha secretion
US5455262A (en) * 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
GR3030751T3 (en) 1999-11-30
US5994312A (en) 1999-11-30
AU695796B2 (en) 1998-08-20
MX9702487A (es) 1998-04-30
FI971412A7 (fi) 1997-04-04
FI971412A0 (fi) 1997-04-04
CZ99697A3 (en) 1997-09-17
WO1996011209A1 (en) 1996-04-18
CZ288436B6 (en) 2001-06-13
DK0784629T3 (da) 1999-10-25
ATE179431T1 (de) 1999-05-15
PL183510B1 (pl) 2002-06-28
DE69509401D1 (de) 1999-06-02
JPH10507170A (ja) 1998-07-14
CN1193978A (zh) 1998-09-23
US6180611B1 (en) 2001-01-30
ES2133807T3 (es) 1999-09-16
DE69509401T2 (de) 1999-08-19
AU3612795A (en) 1996-05-02
FI971412L (fi) 1997-04-04
EP0784629B1 (en) 1999-04-28
PL319503A1 (en) 1997-08-18
NO971537D0 (no) 1997-04-04
HUT77282A (hu) 1998-03-30
JP3787605B2 (ja) 2006-06-21
BR9509237A (pt) 1997-10-21
EP0784629A1 (en) 1997-07-23
CA2201639A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
NO971537L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
DK0728144T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
DK0741694T3 (da) Phenyleddikesyrederivater, fremgangsmåder og mellemprodukter til deres fremstilling og midler indeholdende disse
DK0859784T3 (da) Thiosubstituerede peptider som inhibitorer af metalloproteinaser og TNF-frigivelse
GB9801690D0 (en) Therapeutic agents
NO942618L (no) Imidazolderivater og deres anvendelse som cytokin-inhibitorer
AP2001002348A0 (en) Metalloprotease inhibitors.
NO20002440L (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
NO20051788L (no) Hydantoinderivater og deres anvendelse som TACE-inhibitorer
DK0874808T3 (da) Biphenyl-hydroxamat-inhibitorer for matrix-metalloproteinaser
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BG102918A (en) Biphenylsulphanomide inhibitors of the matrix metalloproteinase
DE60120881D1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren
IL123431A0 (en) Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF)
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
TR200202439T2 (tr) Sodyum hidrojen değiştirici tip 1 önleyici (NHE-1)
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
MXPA05000517A (es) Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz.
EE200200227A (et) Tüüp 1 naatrium-vesinik ioniidi inhibiitori kristallid
GB9723905D0 (en) Heterocyclic compounds having MMP and TNF inhibitory activity